181 related articles for article (PubMed ID: 36330532)
41. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
42. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
[TBL] [Abstract][Full Text] [Related]
43. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O
Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112
[TBL] [Abstract][Full Text] [Related]
44. Alpelisib-Induced Diabetic Ketoacidosis.
Nguyen P; Musa A; Samantray J
Cureus; 2021 May; 13(5):e14796. PubMed ID: 34084688
[TBL] [Abstract][Full Text] [Related]
45. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
46. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
47. Management of Diabetic Ketoacidosis in Adults: A Narrative Review.
Eledrisi MS; Elzouki AN
Saudi J Med Med Sci; 2020; 8(3):165-173. PubMed ID: 32952507
[TBL] [Abstract][Full Text] [Related]
48. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
49. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Dutta S; Kumar T; Singh S; Ambwani S; Charan J; Varthya SB
J Family Med Prim Care; 2022 Mar; 11(3):927-940. PubMed ID: 35495849
[TBL] [Abstract][Full Text] [Related]
50. Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings.
Cook K; Almodallal Y; Martin N; Jatoi A
J Geriatr Oncol; 2021 Sep; 12(7):1114-1117. PubMed ID: 33752998
[TBL] [Abstract][Full Text] [Related]
51. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
[TBL] [Abstract][Full Text] [Related]
52. Profile of diabetic ketoacidosis at the National Diabetes and Endocrine Center in Tripoli, Libya, 2015.
Elkituni A; Elshwekh H; Bendala NM; Atwear WS; Aldaba FA; Fellah AM
Diabetes Metab Syndr; 2021; 15(3):771-775. PubMed ID: 33831773
[TBL] [Abstract][Full Text] [Related]
53. Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis.
Calçada MB; Fernandes L; Soares Costa R; Montezinho S; Martins Duarte F; Frutuoso L; Freitas AR
Clin Pract; 2021 Apr; 11(2):216-218. PubMed ID: 33917274
[TBL] [Abstract][Full Text] [Related]
54. SGLT-2 Inhibitors-a Culprit of Diabetic Ketoacidosis Postbariatric Surgery.
Iqbal QZ; Mishiyev D; Niazi MR; Zia Z; Sattar SBA; Jahanghir A; Quyyumi S
Case Rep Crit Care; 2020; 2020():8817829. PubMed ID: 33204542
[TBL] [Abstract][Full Text] [Related]
55. Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.
Gammons DT; Counselman FL
Clin Pract Cases Emerg Med; 2018 Feb; 2(1):47-50. PubMed ID: 29849291
[TBL] [Abstract][Full Text] [Related]
56. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
[TBL] [Abstract][Full Text] [Related]
57. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
58. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Andrews TJ; Cox RD; Parker C; Kolb J
J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
[TBL] [Abstract][Full Text] [Related]
59. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
60. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
